Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin 5 (IL‑5) is a cytokine critical in the regulation and activation of eosinophils and B cells. It promotes eosinophil maturation, proliferation, activation, survival, and migration. It also stimulates B cell growth and differentiation, increasing immunoglobulin secretion. IL-5 is a key mediator of eosinophilic inflammation and is implicated in asthma, allergic diseases, and autoimmunity. Therapeutics targeting IL-5 have shown efficacy in reducing bronchial mucosal eosinophilia and asthma symptoms.
Anti–IL‑5 monoclonal antibodies neutralize IL-5, preventing it from binding to its receptor on eosinophils, thus reducing eosinophil activation and survival.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 5 (IL‑5).